Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms
ABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2V617F‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2V617F‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk fact...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849413296178855936 |
|---|---|
| author | Guangshuai Teng Ke Shang Yuhui Zhang Yifan Duan Chenxiao Du Yan Wang Yanqi Li Huiqin Zhang Lan Peng Xiaojing Wei Gary Tse Yuan Zhou Gregory Y. H. Lip Tong Liu Wei Yang Minghui Duan Jie Bai |
| author_facet | Guangshuai Teng Ke Shang Yuhui Zhang Yifan Duan Chenxiao Du Yan Wang Yanqi Li Huiqin Zhang Lan Peng Xiaojing Wei Gary Tse Yuan Zhou Gregory Y. H. Lip Tong Liu Wei Yang Minghui Duan Jie Bai |
| author_sort | Guangshuai Teng |
| collection | DOAJ |
| description | ABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2V617F‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2V617F‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model. Results A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke (p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality (p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation (p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β (p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2V617F‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group (p < 0.05). Conclusion AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2V617F‐positive MPN. |
| format | Article |
| id | doaj-art-e4badf96bfda430793417f5a74ddc165 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-e4badf96bfda430793417f5a74ddc1652025-08-20T03:34:09ZengWileyCancer Medicine2045-76342025-07-011413n/an/a10.1002/cam4.71015Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative NeoplasmsGuangshuai Teng0Ke Shang1Yuhui Zhang2Yifan Duan3Chenxiao Du4Yan Wang5Yanqi Li6Huiqin Zhang7Lan Peng8Xiaojing Wei9Gary Tse10Yuan Zhou11Gregory Y. H. Lip12Tong Liu13Wei Yang14Minghui Duan15Jie Bai16Department of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Cardiology The Second Hospital of Tianjin Medical University Tianjin ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin ChinaLiverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool UKDepartment of Cardiology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hemotology Shengjing Hospital of China Medical University Liaoning ChinaDepartment of Hematology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2V617F‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2V617F‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model. Results A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke (p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality (p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation (p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β (p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2V617F‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group (p < 0.05). Conclusion AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2V617F‐positive MPN.https://doi.org/10.1002/cam4.71015atrial fibrillationcytokinesgene mutationJAK2 V617Fmyeloproliferative neoplasms |
| spellingShingle | Guangshuai Teng Ke Shang Yuhui Zhang Yifan Duan Chenxiao Du Yan Wang Yanqi Li Huiqin Zhang Lan Peng Xiaojing Wei Gary Tse Yuan Zhou Gregory Y. H. Lip Tong Liu Wei Yang Minghui Duan Jie Bai Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms Cancer Medicine atrial fibrillation cytokines gene mutation JAK2 V617F myeloproliferative neoplasms |
| title | Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms |
| title_full | Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms |
| title_fullStr | Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms |
| title_full_unstemmed | Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms |
| title_short | Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms |
| title_sort | incidence outcomes and risk factors for atrial fibrillation in patients with jak2v617f positive myeloproliferative neoplasms |
| topic | atrial fibrillation cytokines gene mutation JAK2 V617F myeloproliferative neoplasms |
| url | https://doi.org/10.1002/cam4.71015 |
| work_keys_str_mv | AT guangshuaiteng incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT keshang incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT yuhuizhang incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT yifanduan incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT chenxiaodu incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT yanwang incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT yanqili incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT huiqinzhang incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT lanpeng incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT xiaojingwei incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT garytse incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT yuanzhou incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT gregoryyhlip incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT tongliu incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT weiyang incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT minghuiduan incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms AT jiebai incidenceoutcomesandriskfactorsforatrialfibrillationinpatientswithjak2v617fpositivemyeloproliferativeneoplasms |